{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:46:47Z","timestamp":1791269207487,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 3S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/tp.0000000000001097","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T14:02:26Z","timestamp":1455976946000},"page":"S5-S10","source":"Crossref","is-referenced-by-count":46,"title":["CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients"],"prefix":"10.1097","volume":"100","author":[{"given":"Uwe","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Solidoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrike","family":"Wilkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Enseleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trre.2014.01.001","article-title":"The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.","volume":"28","author":"Roman","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.transproceed.2012.09.035","article-title":"Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy.","volume":"44","author":"Mendez-Eirin","year":"2012","journal-title":"Transplant Proc"},{"key":"R4-2-20210129","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-10-2","article-title":"Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in DR transplant recipients.","volume":"10","author":"Perrottet","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.transproceed.2004.11.066","article-title":"Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.","volume":"37","author":"Fellay","year":"2005","journal-title":"Transplant Proc"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.healun.2007.07.016","article-title":"Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.","volume":"26","author":"Kijpittayarit-Arthurs","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1600-6143.2005.00797.x","article-title":"Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV DR transplant recipients.","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"R9-2-20210129","first-page":"376","article-title":"Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis Am J Transplant.","volume":"13","author":"Schoeppler","year":"2013","journal-title":""},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.healun.2008.02.002","article-title":"High incidence of cytomegalovirus disease in DR heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis.","volume":"27","author":"Gupta","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in DR kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ.","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir.","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N Engl J Med"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1600-6143.2011.03519.x","article-title":"Cytomegalovirus prostatitis in a heart transplant recipient.","volume":"11","author":"Rouphael","year":"2011","journal-title":"Am J Transplant"},{"key":"R17-2-20210129","first-page":"310","article-title":"Cytomegalovirus retinitis after heart transplant: a case report.","volume":"57","author":"Chou","year":"1996","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2008-1067585","article-title":"Hyperimmunoglobulin treatment in CMV infections following heart transplantation.","volume":"113","author":"Cremer","year":"1988","journal-title":"Dtsch Med Wochenschr"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijid.2014.06.009","article-title":"Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.","volume":"28","author":"Kneidinger","year":"2014","journal-title":"Int J Infect Dis"},{"key":"R20-2-20210129","first-page":"4043","article-title":"C, Ussetti Gil P, Laporta R, et al.","volume":"37","year":"2005","journal-title":"Is gammaglobulin anti-CMV warranted in lung transplantation Transplant Proc"},{"key":"R21-2-20210129","first-page":"699","article-title":"Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status J Heart Transplant.","volume":"9","author":"Novick","year":"1990","journal-title":""},{"issue":"Suppl 3","key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1093\/clinids\/10.Supplement_3.S563","article-title":"Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.","volume":"10","author":"Keay","year":"1988","journal-title":"Rev Infect Dis"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2009.02861.x","article-title":"Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.","volume":"10","author":"Eid","year":"2010","journal-title":"Am J Transplant"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1034\/j.1399-3062.2002.t01-1-02008.x","article-title":"Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.","volume":"4","author":"Isada","year":"2002","journal-title":"Transpl Infect Dis"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.healun.2009.03.012","article-title":"Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.","volume":"28","author":"Jaksch","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action.","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir Ther"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00561-13","article-title":"Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.","volume":"58","author":"Minces","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-2-20210129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/519941","article-title":"Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.","volume":"45","author":"Li","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R32-2-20210129","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199911150-00010","article-title":"The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.","volume":"68","author":"Kruger","year":"1999","journal-title":"Transplantation"},{"key":"R33-2-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.","volume":"185","author":"Limaye","year":"2002","journal-title":"J Infect Dis"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"R35-2-20210129","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/tid.12317","article-title":"Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.","volume":"16","author":"Gagermeier","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1073\/pnas.140123497","article-title":"Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.","volume":"97","author":"Emery","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1053-2498(02)00435-7","article-title":"Controversies in lung transplantation: management of cytomegalovirus infections.","volume":"21","author":"Zamora","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.transproceed.2007.06.050","article-title":"The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.","volume":"39","author":"Carbone","year":"2007","journal-title":"Transplant Proc"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.transproceed.2005.09.153","article-title":"Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation.","volume":"37","author":"Sarmiento","year":"2005","journal-title":"Transplant Proc"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T18:56:34Z","timestamp":1654368994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201603001-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":36,"journal-issue":{"issue":"Supplement 3S","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001097","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}